CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ — Brixton Biosciences, a clinical-stage life sciences company developing novel therapies for chronic and acute pain, is delighted to announce that its groundbreaking Coolio™ Therapy has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
Coolio™ Therapy is a novel approach intended to deliver long-lasting pain control in targeted areas with a single injection. Animal models have demonstrated the remarkable capability of this treatment to provide relief for 3+ months, offering a simple and effective solution to pain management.